In addition, across MPN primary samples and mouse models, we demonstrate that α-ketoglutarate (α-KG) supplementation suppresses platelet activation and megakaryopoiesis, in part due to inhibition of cellular metabolism and mTOR pathway signaling, thereby identifying a promising therapeutic strategy for MPN patients. The gene discussed is MTOR; the disease is myeloproliferative disorder.